A detailed history of Moors & Cabot, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Moors & Cabot, Inc. holds 7,191 shares of AZN stock, worth $479,136. This represents 0.03% of its overall portfolio holdings.

Number of Shares
7,191
Previous 7,070 1.71%
Holding current value
$479,136
Previous $551,000 1.63%
% of portfolio
0.03%
Previous 0.03%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$76.67 - $87.62 $9,277 - $10,602
121 Added 1.71%
7,191 $560,000
Q2 2024

Aug 09, 2024

SELL
$66.81 - $80.83 $91,195 - $110,332
-1,365 Reduced 16.18%
7,070 $551,000
Q1 2024

May 08, 2024

BUY
$61.03 - $69.57 $671 - $765
11 Added 0.13%
8,435 $571,000
Q4 2023

Feb 14, 2024

BUY
$61.89 - $69.28 $3,589 - $4,018
58 Added 0.69%
8,424 $567,000
Q3 2023

Nov 07, 2023

BUY
$64.85 - $71.7 $22,048 - $24,378
340 Added 4.24%
8,366 $566,000
Q2 2023

Aug 09, 2023

SELL
$69.91 - $75.81 $194,209 - $210,600
-2,778 Reduced 25.71%
8,026 $574,000
Q1 2023

May 04, 2023

BUY
$63.15 - $71.6 $2,715 - $3,078
43 Added 0.4%
10,804 $749,000
Q4 2022

Feb 09, 2023

BUY
$54.21 - $70.44 $158,293 - $205,684
2,920 Added 37.24%
10,761 $729,000
Q4 2022

Feb 06, 2023

SELL
$54.21 - $70.44 $148,698 - $193,216
-2,743 Reduced 25.92%
7,841 $531,000
Q3 2022

Nov 07, 2022

SELL
$53.02 - $135.75 $28,895 - $73,983
-545 Reduced 4.9%
10,584 $580,000
Q2 2022

Aug 08, 2022

BUY
$59.26 - $71.14 $17,066 - $20,488
288 Added 2.66%
11,129 $735,000
Q1 2022

May 13, 2022

BUY
$55.72 - $67.12 $16,270 - $19,599
292 Added 2.77%
10,841 $719,000
Q4 2021

Feb 14, 2022

BUY
$54.02 - $63.83 $29,927 - $35,361
554 Added 5.54%
10,549 $614,000
Q3 2021

Dec 08, 2021

SELL
$55.56 - $60.79 $65,338 - $71,489
-1,176 Reduced 10.53%
9,995 $600,000
Q3 2021

Nov 05, 2021

BUY
$55.56 - $60.79 $45,059 - $49,300
811 Added 7.83%
11,171 $598,000
Q2 2021

Aug 10, 2021

SELL
$48.42 - $60.18 $38,009 - $47,241
-785 Reduced 7.04%
10,360 $621,000
Q1 2021

May 12, 2021

SELL
$47.16 - $54.44 $7,215 - $8,329
-153 Reduced 1.35%
11,145 $554,000
Q4 2020

Feb 11, 2021

BUY
$48.52 - $58.02 $14,410 - $17,231
297 Added 2.7%
11,298 $563,000
Q3 2020

Nov 09, 2020

SELL
$53.07 - $61.1 $128,429 - $147,862
-2,420 Reduced 18.03%
11,001 $603,000
Q2 2020

Aug 13, 2020

SELL
$43.1 - $55.31 $3,189 - $4,092
-74 Reduced 0.55%
13,421 $706,000
Q1 2020

May 12, 2020

SELL
$37.79 - $51.33 $61,862 - $84,027
-1,637 Reduced 10.82%
13,495 $600,000
Q4 2019

Jan 28, 2020

BUY
$42.46 - $50.46 $5,137 - $6,105
121 Added 0.81%
15,132 $756,000
Q3 2019

Oct 22, 2019

BUY
$40.12 - $45.47 $5,937 - $6,729
148 Added 1.0%
15,011 $665,000
Q2 2019

Jul 18, 2019

BUY
$37.28 - $41.68 $103,750 - $115,995
2,783 Added 23.04%
14,863 $615,000
Q1 2019

May 06, 2019

SELL
$35.49 - $43.02 $428,719 - $519,681
-12,080 Reduced 50.0%
12,080 $488,000
Q1 2019

May 01, 2019

BUY
$35.49 - $43.02 $472,336 - $572,553
13,309 Added 122.65%
24,160 $976,000
Q4 2018

Feb 13, 2019

SELL
$36.86 - $41.49 $11,058 - $12,447
-300 Reduced 2.69%
10,851 $410,000
Q3 2018

Nov 14, 2018

SELL
$34.76 - $39.72 $764 - $873
-22 Reduced 0.2%
11,151 $442,000
Q2 2018

Aug 14, 2018

SELL
$34.55 - $37.05 $46,400 - $49,758
-1,343 Reduced 10.73%
11,173 $396,000
Q1 2018

May 18, 2018

BUY
$32.97 - $36.63 $4,615 - $5,128
140 Added 1.13%
12,516 $438,000
Q4 2017

Feb 13, 2018

SELL
$32.09 - $34.78 $76,342 - $82,741
-2,379 Reduced 16.12%
12,376 $427,000
Q3 2017

Nov 16, 2017

SELL
$28.96 - $34.0 $92,237 - $108,290
-3,185 Reduced 17.75%
14,755 $501,000
Q2 2017

Aug 15, 2017

BUY
N/A
17,940
17,940 $610,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $206B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Moors & Cabot, Inc. Portfolio

Follow Moors & Cabot, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Moors & Cabot, Inc. with notifications on news.